Revolution Medicines initiates EMA rolling review for Daraxonrasib, a pan-RAS(ON) inhibitor, in Phase 3 pancreatic cancer study
Background and Significance of EMA Rolling Review
The European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) has initiated a rolling review of Daraxonrasib (RMC-6236), Revolution Medicines' treatment for metastatic pancreatic cancer. This is because it has been designated as a pilot case for the Cancer Medicines Pathfinder, an initiative introduced under the revised European Union (EU) pharmaceutical law. The regulatory agency's sequential review of clinical data as it becomes available indicates a significant unmet need for this drug. This action reflects a commitment to rapidly provide innovative new drugs to patients with advanced pancreatic cancer.
Distinctiveness of the pan-RAS(ON) Inhibition Mechanism
Daraxonrasib is the first oral, multi-selective pan-RAS(ON) inhibitor that targets the active form of the RAS protein. It overcomes the limitations of existing first-generation therapies, which were limited to specific gene mutations (e.g., KRAS G12C) or inactive (OFF) states, by blocking the GTP-bound 'ON' active state of all RAS family members, including KRAS, NRAS, and HRAS. It acts as a molecular glue that binds to cyclophilin A protein in cells to form a tri-complex, thereby blocking signal transduction. Due to its mechanism of action, it is not limited to specific mutations and has the significant advantage of being applicable to a wide range of RAS-mutated patients.
Unique Data from Phase 3 RASolute 302 Clinical Trial
The recently announced global Phase 3 'RASolute 302' trial results demonstrate that this drug has the potential to change the paradigm of pancreatic cancer treatment. In patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who had failed prior treatment, compared to standard chemotherapy, the median overall survival (mOS) in the daraxonrasib group was 13.2 months, extending survival by two-fold compared to the control group's 6.7 months. This represents a remarkable 60% reduction in the risk of death (hazard ratio, HR 0.40), offering new hope to patients with a life expectancy of only six months. Most importantly, it showed consistent survival benefits regardless of the specific RAS mutation type.
Commercial Competitiveness in the Metastatic Pancreatic Cancer Market
The global market for metastatic pancreatic cancer treatment is estimated at approximately $3.68 billion in 2025 and is expected to grow at a compound annual growth rate of 6.25% to reach $6.75 billion in 2035. Compared to existing, highly toxic chemotherapies such as NALIRIFOX, daraxonrasib is an oral drug with high ease of administration and an improved safety profile. Revolution Medicines has secured a funding agreement with Royalty Pharma for a total of $2 billion, including a $250 million upfront payment, while retaining exclusive rights. This will enable it to proactively establish an independent global commercialization base in the face of competition from large pharmaceutical companies.
Future Prospects and Global Regulatory Milestones
The EMA's expedited review is a significant positive development that further increases the likelihood of daraxonrasib's early entry into the European market. Revolution Medicines plans to significantly shorten the global commercialization timeline by using real-time new drug approval review (RTOR) and rolling submission with the U.S. Food and Drug Administration (FDA). Once approved, it will undoubtedly be a turning point in pancreatic cancer treatment, shifting from conventional chemotherapy to precision medicine based on targeted genes. Investors should monitor the review schedules of each regulatory agency and the release of additional clinical data until formal marketing approval is granted.
Daraxonrasib (RMC-6236) demonstrated survival benefits in a Phase 3 clinical trial, with a median overall survival (mOS) of 13.2 months compared to 6.7 months for the existing chemotherapy control group, which is a significant achievement in capturing the $3.68 billion metastatic pancreatic cancer treatment market in 2025. From a researcher's perspective, it is significant as the first pan-RAS(ON) inhibitor that overcomes the limitations of first-generation KRAS-targeted therapies and inhibits the active state of all core RAS mutations, marking a new era in precision medicine. From the perspective of industry professionals, it is expected that the introduction of a safe and convenient oral targeted therapy as an alternative to highly toxic chemotherapies such as NALIRIFOX will significantly improve patient survival rates. In the short term, an increase in corporate value is expected due to the EMA rolling review and the shortened FDA approval timeline. In the medium to long term, it is likely to become a leading drug in global standard guidelines. The successful clinical data and the $250 million upfront payment agreement with Royalty Pharma support its independent global commercialization capabilities and provide strong investment appeal.